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One important concern in the treatment of diabetes is the maintenance of glycemic levels and the prevention of
diabetic nephropathy. Inducible heme oxygenase 1 (HO-1) is a rate-limiting enzyme thought to have antioxidant
and cytoprotective roles. The goal of the present study was to analyze the effect of HO-1 induction in chronically
hyperglycemic rats. The hyperglycemic rats were divided into two groups: one group, called STZ, was given a
single injection of streptozotocin; and the other group was given a single streptozotocin injection as well as daily
injections of hemin, an HO-1 inducer, over 60 days (STZ + HEME). A group of normoglycemic, untreated rats was
used as the control (CTL).
Body weight, diuresis, serum glucose levels, microalbuminuria, creatinine clearance rate, urea levels, sodium
excretion, and lipid peroxidation were analyzed. Histological alterations and immunohistochemistry for HO-1 and
inducible nitric oxide synthase (iNOS) were assessed. After 60 days, the STZ group exhibited an increase in blood
glucose, diuresis, urea, microalbuminuria, and sodium excretion. There was no weight gain, and there was a
decrease in creatinine clearance in comparison to the CTL group. In the STZ + HEME group there was an
improvement in the metabolic parameters and kidney function, a decrease in blood glucose, serum urea, and
microalbuminuria, and an increase of creatinine clearance, in comparison to the STZ group.
There was glomerulosclerosis, collagen deposition in the STZ rats and increase in iNOS and HO-1 expression. In the
STZ + HEME group, the glomerulosclerosis and fibrosis was prevented and there was an increase in the expression
of HO-1, but decrease in iNOS expression and lipid peroxidation. In conclusion, our data suggest that chronic
induction of HO-1 reduces hyperglycemia, improves glucose metabolism and, at least in part, protects the renal
tissue from hyperglycemic injury, possibly through the antioxidant activity of HO-1.
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Diabetic nephropathy is one of the most serious compli-
cations of diabetes and the most common cause of end-
stage renal failure. At present, diabetic kidney disease
affects about 15%–25% of type I diabetes patients [1]
and 30%–40% of patients with type II diabetes [2]. Dia-
betic nephropathy is characterized by specific renal mor-
phological and functional alterations.* Correspondence: borgesft@nefro.epm.br
1Nephrology Division, Department of Medicine, Universidade Federal de São
Paulo (UNIFESP), São Paulo, Brazil
Full list of author information is available at the end of the article
© 2013 Ptilovanciv et al.; licensee BioMed Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumAccording to clinical studies, the comorbidities of
hypertension, glucose intolerance, and insulin resistance
are considered the major contributors to the develop-
ment of metabolic syndrome and diabetes [3-5].
Reactive oxygen species (ROS) play an important role
in diabetes and its complications [6,7]. Experimental
studies demonstrated the involvement of ROS in the
pathogenesis of diabetes [1] and, more importantly, in
the development of diabetic nephropathy [8-10]. Free
radicals are capable of damaging cellular molecules,
DNA, proteins, and lipids, leading to altered cellular
functions. Antioxidants capable of neutralizing free radi-
cals are effective in preventing experimentally inducedtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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the severity of diabetic complications [13]. ROS are gen-
erated by the electron transport system in mitochondrial
respiration and increase in conditions associated with
enhanced oxidation of substrate such as glucose or free
fatty acids. Other ROS-generating agents of relevance to
insulin-resistant diabetes include uncoupled endothelial
nitric oxide [3,7].
Generally, insulin resistance is accompanied by ele-
vated hyperglycemia, free fatty acids, and adipokines, all
of which are factors known to increase oxidative stress
[14]. There is a consensus that elevated oxidative/inflam-
matory stimuli unleash the cascade of events that
impairs insulin signaling [14]. As such, insulin resistance
may be regarded as a state of increased exposure to ROS
[14], and thus, strategies that concomitantly reduce oxi-
dative stress and glucose/insulin intolerance may retard
and/or annul the complications observed in diabetes.
Among a panel of potential candidate genes related to
oxidative stress, the gene that encodes inducible heme
oxygenase (HO-1) has attracted much attention, and
HO-1 is considered an “emerging molecule” with potent
antioxidant, anti-inflammatory, and anti-proliferative
effects [15,16].
In a physiological system, many cytoprotective
mechanisms are triggered during tissue insult in an
attempt to limit injury. For example, the cellular redox
state modulates the expression of stress proteins such as
hypoxia-inducible factor and heme oxygenase (HO) dur-
ing cellular defense [17,18]. HO is a microsomal enzyme
with inducible (HO-1) and constitutive (HO-2) isoforms
[19]. The HO-catalyzed breakdown of heme yields cyto-
protective products including bilirubin, ferritin, and
carbon monoxide [19]. HO-1 is strongly induced by oxi-
dative stress and it shows cytoprotective effects by the
anti-inflammatory, anti-apoptotic, and anti-proliferative
action of its end by-products [19]. Recent studies
showed that HO-1 induction is protective in many acute
and chronic renal insults [20-24].
The present study observed that the induction of
HO-1 with hemin improved glucose metabolism, as seen
by a decrease in serum glucose and urea, prevented
histological changes observed in diabetic animals, and
induced an increase in creatinine clearance. The
improvement in glucose metabolism may result, in part,
from the antioxidant effect of HO-1.
Material and methods
Animal treatment
Male Wistar rats weighing 200–250 g, 10 per group,
were divided into three groups: the rats in the first
group, the STZ group, were treated with tail injections
of streptozotocin [from Sigma (St. Louis, Mo., USA),
60 mg/kg dissolved in sodium citrate buffer, pH 4.5]; therats in the second group, the STZ +HEME group, were
treated with tail injections of streptozotocin as well as
daily intraperitoneal injections of hemin [0.1 mg/kg]
over 60 days; and the rats in the third group, the control
(CTL) group, received tail injection of citrate buffer and
no hemin.
The animals were allowed free access to standard rat
food and tap water during the experimental protocol. At
0 (baseline), 30, and 60 days after the beginning of ex-
perimental protocols, blood samples were collected from
the lateral tail vein, and the animals were maintained in
metabolic cages over 24 h for urine collection. The ani-
mals were killed 60 days after the beginning of the ex-
perimental protocol, and both the right and left kidneys
were removed for histological analysis. Biochemical
parameters in the plasma and urine samples were deter-
mined. The experimental protocol was approved by the
ethics committee of the Universidade Federal de São Paulo.
Biochemical analysis
Blood samples were taken from the tails of all the rats
and plasma glucose concentrations were determined
(Accuchek, Boehringer Mannheim, Indianapolis, Ind.,
USA). The levels of blood creatinine and blood urea
were assayed spectrophotometrically according to stand-
ard procedures by using commercially available diagnos-
tic kits (Labtest Diagnostica, Minas Gerais, Brazil).
Creatinine was determined by a colorimetric method
based on the Jafé reaction [25] and the creatinine clear-
ance was assessed. Urea was determined using a colori-
metric assay based on urease activity [26]. Levels of
creatinine and urea were expressed in mg/dL. Urine
sodium concentrations were determined with a Micronal
B462 flame photometer (São Paulo, Brazil). Sodium
(ENa) excretions were expressed as mEq/24 h.
The concentrations of albumin in 24-h urine sam-
ples were assessed using commercially available
enzyme-linked immunosorbent assays (ELISA) (Bethyl
laboratories, USA). The optical density of each sample
was determined using an Ultra Microplate Reader
(EL808; Bio-Tek Instruments, Winooski, VT, USA)
and expressed as mg/24 h for urine concentrations.
Lipid peroxidation
Lipid peroxidation was determined in urine samples by
quantifying thiobarbituric acid reactive substances
(TBARS). The reactive substances combine with thiobar-
bituric acid, forming a red compound whose concentra-
tion can be assessed spectrophotometrically at an
absorbance of 535 nm [27]. Malondialdehyde (MDA)
was used as the standard curve, and the results were
expressed as nM of MDA/mg creatinine. Urine samples
were added to a solution of 0.375% thiobarbituric acid,
15% trichloroacetic acid, and 0.25 N HCl (Sigma-
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continuously agitated while being heated to 95°C for
20 min. Subsequently, the samples were allowed to cool
to room temperature. The assessment of the creatinine
level in the urine samples was performed as previously
described and used to normalize the results of MDA.
Urinary hydroperoxide
Urinary levels of hydroperoxides were measured by the
ferrous oxidation with Xylenol Orange, FOX2 assay for
lipid hydroperoxide [28]. Briefly, 100 μl aliquots of urine
were transferred into microcentrifuge vials with the
addition of 900 μl FOX2 reagent. After incubation at
room temperature for a further 30 min, the vials were
centrifuged at 12,000 rpm at 25°C for 10 min. Absorb-
ance of the supernatant was then determined at 560 nm.
Lipid hydroperoxide content in urine samples was deter-
mined according absorption molar coefficient (3 10 [4]
M-1 cm-1). The assessment of the creatinine level in the
urine samples was performed as previously described
and used to normalize the results of urinary
hydroperoxides.
Nitric oxide determination
Nitric oxide was determined in the 24-h urine samples
by the Griess method. Briefly, a mixture of 1% sulfanila-
mide (in 5% H3PO4) and 0.1% naphthylethylenediamine
solution (Sigma, Saint Louis, USA) was added to the
samples and the absorbance at 546 nm was measured
using a GENESYS 2 spectrophotometer (Spectronic
Instruments, Rochester, USA). Nitrite, one of the stable
metabolites of NO, was then estimated from a standard
curve constructed using NaNO2. The urine volume was
used to normalize the quantification.
Histological analysis
The kidneys were dissected along the non-hilar axis and
fixed in 10% phosphate-buffered formalin (Erviegas, São
Paulo, Brazil). Kidney sections were fixed with 4% buf-
fered paraformaldehyde and then embedded in paraffin
(Erviegas, São Paulo, Brazil). Next, 4-μm thick sections
were prepared for hematoxylin and eosin (HE; Erviegas,
São Paulo, Brazil) staining, and picro-sirius red staining
(PC; Erviegas), and then examined by light microscopy
in a blinded manner.
Glomerulosclerosis was semiquantitatively evaluated
on HE-stained paraffin sections as follows: grade 0, nor-
mal glomerulus; grade 1, beginning mesangial expan-
sion/thickening of the basement membrane and/or
irregular lumina of capillaries; grade 2, mild/moderate
segmental hyalinosis/sclerosis involving less than 50% of
the glomerular tuft; grade 3, diffuse glomerular hyalino-
sis/sclerosis involving more than 50% of the tuft; and
grade 4, diffuse glomerulosclerosis with total tuftobliteration and collapse. Results were reported as the
mean ± standard deviation and expressed as arbitrary
units (AUs).
Immunohistochemistry
The kidney slices were deparaffinized and rehydrated.
Endogenous peroxidase activity was blocked with 5%
H2O2 in absolute methanol for 10 min at room
temperature. To expose the antigens, kidney sections
were boiled in a target retrieval solution [1 mmol/L tris
(hydroxymethyl)aminomethane (Tris), pH 9.0, with
0.5 mM ethylene glycol tetraacetic acid (EGTA)] for
10 min. Nonspecific binding was prevented by incubat-
ing the sections in phosphate buffered saline (PBS) con-
taining 1% bovine serum albumin (BSA), 0.05% saponin,
and 0.2% gelatin. Sections were incubated with primary
antibodies against HO-1 (1: 200, rabbit anti-human;
Enzo Life Sciences, Michigan, USA) and iNOS (1: 200,
rabbit anti-rat IgG; ABCAM, MA). Protein expression
was measured using a streptavidin peroxidase kit (Dako,
California, USA). Sections were stained with diamino-
benzidine for HO-1 and iNOS detection and then coun-
terstained with hematoxylin. Signals in negative control
sections were absent. Digital photomicrographs were
taken through a Nikon Eclipse E600 upright microscope
equipped with Plan Apo objectives and connected to a
Dell workstation computer through the PixeLINKW
Microscope Camera Software (Ottawa, Canada). Eight or
nine photomicrographs along the kidney cortex were
taken and the light brown staining was quantified
(Axionvision microscope program) and averaged for
each rat. The values obtained were expressed as pixels
per field.
Statistical analysis
The results are expressed as a mean ± SE. The data were
analyzed by one-way analysis of variance (ANOVA)
followed by the Tukey tests. Nonparametric data were
analyzed by the Dunn tests and p < 0.05 was considered
statistically significant.
Results
Table 1 shows the biochemical parameters observed in
the three study groups, (STZ), (STZ +HEME), and
(CTL).
Long-term diabetes induced by streptozotocin was
associated with significant increase in the blood glucose
level after 30 (STZ: 470 ± 24 versus CTL: 113 ± 12 mg/
dL, p < 0.01) and 60 (STZ: 554 ± 29 versus CTL: 109 ±
2 mg/dL, p < 0.01) days of treatment, and progressive
body weight loss after 30 (STZ: 241 ± 15 versus CTL:
364 ± 24 g, p < 0.01) and 60 (STZ: 255 ± 20 versus CTL:
436 ± 17 g, p < 0.01) days of treatment in comparison to
CTL. Hemin significantly decreased the blood glucose
Table 1 Physiological parameters
Groups CTL STZ STZ + HEME
day 0 day 30 day 60 day 60 day 30 day 60 day 60 day 30 day 60
BW, g 278 ± 14 364 ± 24 436 ± 17 264 ± 10 241 ± 15* 255 ± 20* 247 ± 5 213 ± 18* 226 ± 18*
Uv, ml 13 ± 2 14 ± 1 12 ± 1 13.1 ± 1 69 ± 11* 57 ± 18* 16 ± 2 83 ± 5* 86 ± 2*
BG, mg/dl 86 ± 4 113 ± 12 109 ± 2 84 ± 4 470 ± 24* 554 ± 29* 80 ± 3 557 ± 27* 338 ± 24*#
U, mg/dl 45 ± 3 47 ± 4 44 ± 2 48 ± 2 91 ± 11* 88 ± 8* 48 ± 2 70 ± 5* 59 ± 6*#
ClCr, ml/min - - 1.02 ± 0.07 - - 0.12 ± 0.03* - - 0.28 ± 0.02*#
UA, mg/24h 0.50 ± 0.08 0.33 ± 0.06 0.28 ± 0.04 0.81 ± 0.09 1.67 ± 0.98 3.50 ± 1.04* 0.42 ± 0.05 1.05 ± 0.63 0.85 ± 0.42
UNaV, mEq/24h 0.7 ± 0.1 0.8 ± 0.1 0.7 ± 0.1 0.7 ± 0.1 2.8 ± 0.8* 0.9 ± 0.3 1.0 ± 0.1 2.4 ± 0.5* 1.4 ± 0.2*
Data were expressed as the mean ± SEM. The significance level for a null hypothesis was set at 5% (p < 0.05). BW (body weight), Uv (urinary volume), BG (blood
glucose), U (serum urea), ClCr (creatinine clearance), UA (urinary albumin) and UNaV (urinary sodium excretion) were analyzed in CTL, STZ and STZ+HEME groups.
(*) versus CTL and (#) versus STZ.
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there was no difference in the body weight (STZ +
HEME: 226 ± 18 g, p = 0.36) in STZ +HEME animals
after 60 days, when compared to the STZ group.
There was a significant increase in diuresis in STZ and
STZ +HEME groups after 30 (STZ: 69 ± 11; STZ +
HEME: 83 ± 5 versus CTL: 14 ± 1 mL/24 h, p < 0.01) and
60 (STZ: 57 ± 18; STZ +HEME: 86 ± 2 versus CTL: 12 ±
1 mL/24 h, p < 0.01 and p < 0.05 respectively) days when
compared to CTL.
The glomerular filtration was assessed by microalbu-
minuria, and it was observed that the STZ group had a
significant increase in microalbuminuria after 30 (STZ:
1.67 ± 0.98 versus CTL: 0.33 ± 0.06 mg/24 h, p = 0.22)
and 60 (STZ: 3.50 ± 1.04 versus CTL: 0.28 ± 0.04 mg/
24 h, p < 0.01) days (Table 1). Treatment with hemin
significantly inhibited the increase in microalbuminuria
when compared to the STZ group (STZ: 3.50 ± 1.04
versus STZ +HEME: 0.85 ± 0.42 mg/24 h, p < 0.01).
Renal function was assessed by creatinine clearance
and urea levels. Table 1 shows that there was a signifi-
cant decrease in creatinine clearance in STZ (0.12 ±
0.03 mL/min, p < 0.01) compared to CTL (1.02 ±
0.07 mL/min) after 60 days of treatment. There was a
small but significant increase in creatinine clearance in
the STZ +HEME (0.28 ± 0.02 mL/min, p < 0.01) group
when compared to the STZ group (p < 0.01).
The plasma urea concentration significantly increased
in the STZ group (30 days: 91 ± 11, 60 days: 88 ± 8 mg/
dL, p < 0.01) when compared to the CTL group (30 days:
47 ± 4, 60 days: 44 ± 2 mg/dL) (Table 1). In the STZ +
HEME group (30 days: 70 ± 5, 60 days: 59 ± 6 mg/dL),
this increase was significantly prevented after 60 days
(p = 0.03) in comparison to the STZ group (Table 1).
Tubular lesion was assessed by excretion of sodium.
There was a significant increase in sodium excretion
after 30 days (2.8 ± 0.8 mEq/24 h, p = 0.03) but not 60
(0.9 ± 0.3 mEq/24 h, p = 0.66) days in the STZ group and
30 (2.4 ± 0.5 mEq/24 h, p = 0.02) and 60 (1.4 ± 0.2 mEq/24 h, p = 0.01) days in the STZ +HEME group in com-
parison to the CTL group after 30 (0.8 ± 0.1 mEq/24 h)
and 60 (0.7 ± 0.1 mEq/24 h) days, respectively (p < 0.05),
but there was no difference in sodium excretion between
the STZ and STZ +HEME groups.
Figure 1 shows the histological sections of renal tissue
staining for HE, and picro-sirius red. When compared
with the control group, there was glomerular hyper-
trophy, collagen deposition in STZ group. There was an
improvement in these alterations in the STZ +HEME
group, we observed structural collagen deposition. The
polarized light showed the immature collagen (green)
and intermediate in CTL and SZT +HEME groups,
while STZ groups showed mature collagen (red) prob-
ably around tubules and vessels. The score of glomerulo-
sclerosis was significantly increased in the STZ group
(0.90 ± 0.01 AU) compared with the CTL group (0.19 ±
0.03 AU), whereas hemin treatment (STZ +HEME)
reduced the glomerulosclerosis (0.55 ± 0.02 AU) com-
pared with the STZ group.
HO-1 and iNOS staining were examined by immuno-
histochemistry. There was a small amount of staining
for HO-1 (STZ: 32.1 ± 8.4 versus CTL: 11.6 ± 1.9 pixels
per field) and a significant increase for iNOS (STZ:
122 ± 13.2 versus CTL: 1.6 ± 0.4 pixels per field) staining
in the STZ group in comparison with the CTL
group. Treatment with hemin (STZ +HEME) signifi-
cantly increased the expression of HO-1 (STZ +HEME:
162.2 ± 63.9 pixels per field), as expected, but inhibit the
staining for iNOS (34.6 ± 4.8 pixels per field) (Figure 1).
We also evaluated the urinary nitric oxide metabolites.
We observed an increase in urinary nitric oxide in STZ
(43.7 ± 6.8 μM/day) after 60 days of treatment compared
to the CTL (6.7 ± 2.4 μM/day) group in 24 h urine
volume. In STZ +HEME group (11.3 ± 2.9 μM/day)
prevented the increase of urinary nitric oxide.
There was no difference in the lipid peroxidation
between the groups at baseline; however there was a
significant increase in TBARS in the STZ group (STZ:
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Figure 1 (A) Light microscopy of kidney sections stained with hematoxylin-eosin at 10x (HE 100), Picro-sirius red 20x (PC 200), 10x
(polarized light, PC 100) and immunohistochemistry for HO-1 (200), iNOS (200) in control rats (CTL), rats treated with streptozotocin
(STZ), and rats treated with STZ and daily injection of hemin (STZ+HEME). (B) Quantitative analyses of kidney sections stained for heme-
oxygenase-1 (HO-1), induced nitric oxide synthase (iNOS) expressed as pixels/field, stained with HE (glomerulosclerosis) expressed as arbitrary
units (AU). Data were expressed as the mean ± SEM. The significance level for a null hypothesis was set at 5% (p < 0.05) (*) significantly different
in comparison to CTL group and (#) significantly different in comparison to STZ group.
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creatinine) after 60 days (p < 0.05). Additionally, we
observed a significant decrease in TBARS in the STZ +
HEME group (STZ +HEME: 44.0 ± 0.8 versus STZ:
93.5 ± 17.0 nM MDA/mg of creatinine) compared with
the STZ group in the same period (Figure 2). This result
was corroborated by the hydroperoxide production.
There was an increase in STZ group (STZ: 2.39 ± 0.31
versus CTL: 0.99 ± 0.18 μM/mg of creatinine) after
60 days that was inhibited in the STZ +HEME group
(STZ +HEME: 0.50 ± 0.05 μM/mg of creatinine).
Discussion
One of the major concerns of current diabetes treatment
is the maintenance of glycemic levels within a narrow
range, reflecting the recommendations of the Diabetes
Control and Complications Trial [29]. However, such
tight glycemic control may not be feasible, and even
patients who diligently regulate their blood glucose
levels are still vulnerable to the many complications that
characterize diabetes.
There are obvious therapeutic benefits to studying
diabetic nephropathy and evaluating novel antidiabetic
strategies that are capable of improving the chronic
consequences of hyperglycemia.
In the present study, we provide evidence that HO-1
induction could confer protection against metabolic
alterations and, at least in part, in kidney histological
alterations observed in diabetic animals.
HO-1, the inducible isoform of the HO system, is a
rate-limiting enzyme, which converts heme into equimo-
lar amounts of iron, carbon monoxide, and biliverdin.
HO-1 is thought to have antioxidant and cytoprotective
roles [30]. The products of the HO reaction, biliverdinA B
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Figure 2 (A) TBARS levels (nM/mg of creatinine) and (B) Hydroperoxid
with streptozotocin (STZ) and rats treated with streptozotocin + hem
mean ± SEM. The significance level for a null hypothesis was set at 5% (p <
(#) significantly different in comparison to STZ group.and carbon monoxide, can be toxic at very high concen-
trations. However, recent evidence indicates that they
are not toxic at physiological concentrations in normal
cells, and that they may have important antioxidant,
anti-inflammatory, or anti-apoptotic properties [31,32].
The level of HO-1 protein is increased in diabetes.
Our work demonstrated that in hyperglycemic rats trea-
ted with streptozotocin, the HO-1 expression in the
kidneys was increased, and that in similar animals that
were treated with hemin, the induction of HO-1
improved the histological alterations observed.
The hyperglycemia induced by streptozotocin pro-
moted diuresis and inhibited weight gain. In our experi-
ment, the treatment with hemin decreased blood
glucose and urea, as already observed in other studies.
Correa-Costa observed that hemin treatment improved
the kidney function and reversed the fibrosis observed in
chronic kidney disease induced by ureteral unilateral ob-
struction [32]. Hemin improved the glucose metabolism
in hyperglycemic and spontaneously hypertensive rats
[33], and type 2 diabetic subjects showed an increase in
HO-1 [34].
In streptozotocin-induced hyperglycemic rats, glom-
erular alterations such as microalbuminuria, increase in
urea levels, and decrease in creatinine clearance, as well
as tubular disorders, and increased excretion of sodium
were observed. The treatment of hyperglycemic animals
with hemin over 60 days inhibited the microalbumi-
nuria, decreased urea levels, and induced a slight
increase in creatinine clearance, but did not improve the
level of sodium excretion. The effect of hemin on micro-
albuminuria has also been shown by others [32].
Our histological analysis showed that the renal tissues
from diabetic animals treated with hemin were protected0
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es (μM/mg of creatinine) in the control group (CTL), rats treated
in (STZ+HEME) at 0, 30 and 60 days. Data were expressed as the
0.05) (*) significantly different in comparison to CTL group and
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sclerosis was significantly inhibited and the fibrotic
collagen deposition was prevented by hemin treatment.
The protective effects of HO-1 have been demon-
strated in vivo; it was found that the induction of HO-1
in mice prevented diabetes-induced kidney injury. This
effect resulted from oxidative stress inhibition [35].
Additionally, the interaction between heme oxygenase
and nitric oxide (NO) has already been observed in the
kidney [36]. The HO-1 induction inhibits NO synthase
[37], however fewer works have demonstrated the inter-
action between these systems in the kidneys of diabetic
animals. The present study showed that treatment with
hemin also inhibited NO synthase expression and urin-
ary nitric oxide production in 24-h urine, and the inhib-
ition of NO could be involved in the protective effect of
hemin.
Histological analysis showed that there was a preven-
tion of tubular injury, fibrosis, induction of HO-1 and
inhibition of iNOS and NO in those subjects that had
been treated with hemin. This effect may result, in part,
from inhibition of lipid peroxidation [33].
In conclusion, our data suggest that chronic induction
of HO-1 reduces hyperglycemia, improves glucose
metabolism in diabetic animals, and protects the renal
tissue from hyperglycemic injury, possibly resulting from
antioxidant activity.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributios
EONP, GSF, LCT, LAR, EAP and MBC conducted the experiments; EONP and
FTB design the experimental protocol; FTB and GAA wrote the manuscript,
MJS and NS critically evaluate the results and revised the manuscript. All
authors read and approved the final manuscript.
Author details
1Nephrology Division, Department of Medicine, Universidade Federal de São
Paulo (UNIFESP), São Paulo, Brazil. 2Morphology Department, Universidade
Federal de São Paulo (UNIFESP), São Paulo, Brazil.
Received: 21 July 2012 Accepted: 9 January 2013
Published: 16 January 2013
References
1. Hovin P, Tarnow L, Rossingo K, et al: Decreasing incidence of severe
diabetic microangiopathy in type 1 diabetes. Diabetes Care 2003,
26(4):1258–1264.
2. Yokoyama H, Okudaira M, Otani T, et al: Higher incidence of diabetic
nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in
Japan. Kidney Int 2000, 58(1):302–311.
3. Paravicini TM, Touyz RM: NADPH oxidases, reactive oxygen species, and
hypertension: clinical implications and therapeutic possibilities. Diabetes
Care 2008, 31(Suppl 2):S170–S180.
4. Evans JL, Goldfine ID, Maddux BA, Grodsky GM: Oxidative stress and stress-
activated signaling pathways: a unifying hypothesis of type 2 diabetes.
Endocr Rev 2002, 23:599–622.
5. Evans JL, Goldfine ID, Maddux BA, Grodsky GM: Are oxidative stress-
activated signaling pathways mediators of insulin resistance and β-cell
dysfunction? Diabetes 2003, 52:1–8.6. Ha H, Lee HB: Reactive oxygen species as glucose signaling molecules in
mesangial cells cultured under high glucose. Kidney Int Suppl 2000,
58(77):S19–S25.
7. Iglesias-De La Cruz MC, Ruiz-Torres P, Alcamí J, et al: Hydrogen peroxide
increases extracellular matrix mRNA through TGF-β in human mesangial
cells. Kidney Int 2001, 59(1):87–95.
8. Matteucci E, Giampietro O: Oxidative stress in families of type 1 diabetic
patients. Diabetes Care 2000, 23(8):1182–1186.
9. Oberley LW: Free radicals and diabetes. Free Radic Biol Med 1988,
5(2):113–124.
10. Baynes JW, Thorpe SR: The role of oxidative stress in diabetic
complications. Curr Opin Endocrinol Diab 1997, 3(4):277–284.
11. Lipinski B: Pathophysiology of oxidative stress in diabetes mellitus.
J Diabetes Complications 2001, 15(4):203–210.
12. Kubisch HM, Wang J, Bray TM, Phillips JP: Target overexpression of Cu/Zn
superoxide dismutase protects pancreatic β-cells against oxidative
stress. Diabetes 1997, 46(10):1563–1566.
13. Naziroglu M, Cay M: Protective role intraperitoneally administered
vitamin E and selenium on the oxidative defense mechanisms in rats
with diabetes induced by streptozotocin. Biol Stress Elem Res 2001,
47:475–488.
14. Vinayagamoorthi R, Bobby Z, Sridhar MG: Antioxidants preserve redox
balance and inhibit c-Jun-N-terminal kinase pathway while improving
insulin signaling in fat-fed rats: evidence for the role of oxidative stress
on IRS-1 serine phosphorylation and insulin resistance. J Endocrinol 2008,
197:287–296.
15. Morse D, Choi AM: Heme oxygenase-1: the emerging molecule has
arrived. Am J Respir Cell Mol Biol 2002, 27:8–16.
16. Bruce CR, Carey AL, Hawley JA, Febbraio MA: Intramuscular heat shock
protein 72 and heme oxygenase-1 mRNA are reduced in patients with
type 2 diabetes: evidence that insulin resistance is associated with a
disturbed antioxidant defense mechanism. Diabetes 2003,
52(9):2338–2345.
17. Sasaki T, Takahashi T, Maeshima K, et al: Heme arginate pretreatment
attenuates pulmonary NF-kappaB and AP-1 activation induced by
hemorrhagic shock via heme oxygenase-1 induction. Med Chem 2006,
2(3):271–274.
18. Abraham NG, Kappas A: Pharmacological and clinical aspects of heme
oxygenase. Pharmacol Rev 2008, 60(1):79–127.
19. Kirkby KA, Adin CA: Products of heme oxygenase and their potential
therapeutic applications. Am J Physiol Renal Physiol 2006, 290(3):F563–F571.
20. Kim JH, Yang JI, Jung MH: Heme oxygenase-1 protects rat kidney from
ureteral obstruction via an antiapoptotic pathway. J Am Soc Nephrol 2006,
17(5):1373–1381.
21. Desbuards N, Hyvelin JM, Machet MC MC, et al: Heme oxygenase-1
inducer hemin attenuates the progression of remnant kidney model.
Nephron Exp Nephro 2009, 113(1):35–44.
22. Gonçalves GM, Cenedeze MA, Feitoza CQ, et al: The role of heme
oxygenase 1 in rapamycin-induced renal dysfunction after ischemia and
reperfusion injury. Kidney Int 2006, 70(10):1742–1749.
23. Goodman AI, Olszanecki R, Yang LM, et al: Heme oxygenase-1 protects
against radiocontrast-induced acute kidney injury by regulating anti-
apoptotic proteins. Kidney Int 2007, 72(8):945–953.
24. Rezzani R, Rodella L, Buffoli B, et al: Change in renal heme oxygenase
expression in cyclosporine A-induced injury. J Histochem Cytochem 2005,
53(1):105–112.
25. Taussky HH: A microcolorimetric determination of creatine in urine by
the Jaffe reaction. J. Biol. Chem 1954, 208(2):853–861.
26. Bergmeyer HU: Methods of Enzymatic Analysis. 9th edition. Flórida: VHC
Publishers; 1985:425–435.
27. Beuge JA, Aust SD: The thiobarbituric acid assay. Methods Enzymol. 1978,
52(427):306–307.
28. Meisner P, Gębicki JL: Determination of hydroperoxides in aqueous
solutions containing surfactants by the ferrous oxidation-xylenol orange
method. Acta Bioquimica polonica 2009, 56(3):523–527.
29. King H, Aubert RE, Herman WH: Global burden of diabetes, 1995–2025:
prevalence, numerical estimates, and projections. Diabetes Care 1998,
21(9):1414–1431.
30. Shiraishi F, Curtis LM, Truong L, et al: Heme oxygenase-1 gene ablation or
expression modulates cisplatin-induced renal tubular apoptosis. Am J
Physiol Renal Physiol 2000, 278(5):726–736.
Ptilovanciv et al. Diabetology & Metabolic Syndrome 2013, 5:3 Page 8 of 8
http://www.dmsjournal.com/content/5/1/331. Agarwal A, Nick HS: Renal response to tissue injury: lessons from heme
oxygenase-1 Gene Ablation and expression. J Am Soc Nephrol 2000,
11(5):965–973.
32. Correa-Costa M, Semedo P, Monteiro AP, et al: Induction of heme
oxygenase-1 can halt and even reverse renal tubule-interstitial fibrosis.
PLoS One 2010, 5(12):e14298.
33. Ndisang JF, Lane N, Syed N, Jadhav A: Up-regulating the heme oxygenase
system with hemin improves insulin sensitivity and glucose metabolism
in adult spontaneously hypertensive rats. Endocrinology 2009,
151(2):549–560.
34. Bao W, Song F, Li X, et al: Plasma heme oxygenase-1 concentration is
elevated in individuals with type 2 diabetes mellitus. PLoS One 2010,
5(8):12371.
35. Goodman AI, Chander PN, Rezzani R, et al: Heme oxygenase-2 deficiency
contributes to diabetes-mediated increase in superoxide anion and renal
dysfunction. J Am Soc Nephrol 2006, 17(4):1073–1081.
36. Furuichi M, Yokozuka M, Takemori K, Yamanashi Y, Sakamoto A: The reciprocal
relationship between heme oxygenase and nitric oxide synthase in the
organs of lipopolysaccharide-treated rodents. Biomed Res 2009, 30(4):235–243.
37. Datta PK, Gross EJ, Lianos EA: Interactions between inducible nitric oxide
synthase and heme oxygenase-1 in glomerulonephritis. Kidney Int 2002,
61(3):847–850.
doi:10.1186/1758-5996-5-3
Cite this article as: Ptilovanciv et al.: Heme oxygenase 1 improves
glucoses metabolism and kidney histological alterations in diabetic rats.
Diabetology & Metabolic Syndrome 2013 5:3.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
